PRU has successfully completed its scheduled FDA re-inspection with zero observations — reaffirming our standing as one of the MENA region's most rigorously compliant Contract Research Organizations.
The inspection covered our bioanalytical laboratory, clinical trial unit, quality systems, and data integrity practices. FDA inspectors examined our LC-MS/MS method validation records, sample chain-of-custody documentation, and electronic data management systems over a three-day period.
What zero observations means
An FDA inspection concluding with zero observations — No Action Indicated (NAI) — is the highest possible outcome. It signals that our quality systems, documentation, and laboratory operations fully meet FDA standards without any corrective action required.
What this means for our clients
Studies conducted at PRU carry the full weight of FDA-inspected facility credentials. Pharmaceutical companies submitting ANDAs or NDAs to the FDA can reference PRU data with confidence — our inspection history speaks directly to data reliability and regulatory acceptance.
